alexa Attention Deficit Hyperactivity Disorder and Disruptive Mood Dysregulation Disorder Treatment with Olanzapine and Methylphenidate: A Case Report | OMICS International | Abstract
ISSN: 2572-0791

Clinical Depression
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Case Report

Attention Deficit Hyperactivity Disorder and Disruptive Mood Dysregulation Disorder Treatment with Olanzapine and Methylphenidate: A Case Report

Zeynep Vatansever*, Hatice Ünver**, Duygu Karagöz*, Nursu Çakin Memik*and Özlem Yildiz Gündogdu*

Kocaeli University, Medical Faculty Child and Adolescent Psychiatry, Umuttepe, Kocaeli, Turkey

*Corresponding Author:
Ünver H
Kocaeli University
Medical Faculty Child and Adolescent Psychiatry
Umuttepe, Kocaeli, Turkey
Tel: +0905447693472
E-mail: [email protected]

Received Date: November 02, 2015 Accepted Date: November 05, 2015 Published Date: Novomber 30, 2015

Citation: Vatansever Z, Ünver H, Karagöz D, Memik NÇ, Gündogdu ÖY (2015). Attention Deficit Hyperactivity Disorder and Disruptive Mood Dysregulation Disorder Treatment with Olanzapine and Methylphenidate: A Case Report. Clin Depress 1:105. doi:10.4172/2572-0791.1000105

Copyright: © 2015 Vatansever Z,et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Attention deficit hyperactivity disorder (ADHD) is one of the most common disorders in childhood which deficits of inattention, hyperactivity and impulsive behavior. Disruptive mood dysregulation disorder is characterized by severe recurrent temper outbursts that are inconsistent with developmental level and manifest verbally or behaviorally. The disorder can co-exist with ADHD and conduct disorder. In treatment of ADHD most common used pharmacological agent is methylphenidate. Atypical antipsychotics (e.g. risperidone, aripiprazole, olanzapine) can be added to treatment in some cases because of unsatisfactory clinical response and comorbidities such as conduct disorder, pervasive developmental disorders, disruptive mood dysregulation disorder, mental retardation. Olanzapine is one of the Food and Drug Administration approved atypical antipsychotics which antagonizing the dopamine (D1, D2, D4), serotonine (5-HT2A, 5-HT2C, 5-HT6), histamine (H1), alpha1- adrenergic and muscarinic (especially M1) receptors. It is used increasingly for the treatment mood disorders, schizophrenia, conduct disorder and pervasive developmental disorders at child and adolescent psychiatry clinics. Studies pointed that olanzapine causes mostly dry mouth, weith gain, increase apetite, sedation and hyperlipidemia. In this article, we report a 8-year-old male patient treated with olanzapine and OROS methylphenidate who have ADHD, disruptive mood dysregulation disorder and conduct disorder. This issue want to get attention that these two psychopharmacologic agent is usable concominantly ADHD and comorbidities.


Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

social_politic[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7